➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
Johnson and Johnson
Baxter
Express Scripts

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,381,428


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,381,428
Title:Stabilized lanthanum carbonate compositions
Abstract:Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.
Inventor(s): Ferdinando; Josephine Christine (Tadley, GB), Davies; Peter Neil (Basingstoke, GB)
Assignee: Shire International Licensing B.V. (NL)
Application Number:11/272,569
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,381,428
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,381,428

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-004 Nov 23, 2005 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE ⤷  Try it Free
Takeda Pharms Usa FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-001 Oct 26, 2004 DISCN No No ⤷  Try it Free ⤷  Try it Free REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE ⤷  Try it Free
Takeda Pharms Usa FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-002 Oct 26, 2004 AB RX Yes No ⤷  Try it Free ⤷  Try it Free REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE ⤷  Try it Free
Takeda Pharms Usa FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-003 Nov 23, 2005 AB RX Yes No ⤷  Try it Free ⤷  Try it Free REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,381,428

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 056609 ⤷  Try it Free
Austria 460169 ⤷  Try it Free
Austria 9809 ⤷  Try it Free
Australia 2004266050 ⤷  Try it Free
Australia 2006313490 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Mallinckrodt
Merck
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.